In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations

In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations

Laura A Tan, Nileshkumar Gajipara, Lei Sun, Maria Bacolod, Ying Zhou, Mark Namchuk, Jacobi I Cunningham Alkermes, Inc, Waltham, MA, USACorrespondence: Laura A Tan, Alkermes, Inc, 852 Winter St, Waltham, MA, 02451, USA, Tel +1 781-609-6390, Email laura.tan@alkermes.comIntroduction: The atypical antip...

Full description

Bibliographic Details
Main Authors:	Tan LA, Gajipara N, Sun L, Bacolod M, Zhou Y, Namchuk M, Cunningham JI
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-11-01
Series:	Neuropsychiatric Disease and Treatment
Subjects:	alks 3831 bipolar i disorder lybalvi olanzapine opioid receptor schizophrenia
Online Access:	https://www.dovepress.com/in-vivo-characterization-of-the-opioid-receptorbinding-profiles-of-sam-peer-reviewed-fulltext-article-NDT

Similar Items

Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics
by: LI Daojun, et al.
Published: (2018-05-01)

A validated RP-UPLC method for estimation of Samidorphan and Olanzapine in mixed powder and combined tablets
by: Krishnaphanisri Ponnekanti, et al.
Published: (2023-11-01)

Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review
by: S. Andrea Laguado, PharmD, BCPS, BCPP, et al.
Published: (2023-08-01)

Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature
by: Andreea Teodorescu, et al.
Published: (2017-08-01)

That’s not my family: The undercover bipolar patient
by: M.F. Tascon Guerra
Published: (2021-04-01)

Naltrexone Implant for Opioid Use Disorder
by: Amber N. Edinoff, et al.
Published: (2021-12-01)

Bioanalytical method development and validation for the simultaneous estimation of Olanzapine and Samidorphan in rabbit plasma by using HPLC–MS/MS and application to pharmacokinetic study
by: Rambabu Kantipudi, et al.
Published: (2024-01-01)

Organizational and managerial culture as a facilitator or inhibitor of organizational transformation
Published: (2003)

Tubulin/microtubules as novel clozapine targets
by: Mizuki Hino, et al.
Published: (2022-03-01)

A prospective naturalistic multicenter study on choice of parenteral medication in psychiatric emergency settings in Japan
by: Kotaro Hatta, et al.
Published: (2018-09-01)

Distributed decision and communication problems in tactical USAF command and control
Published: (2003)

Reverse Intermetamorphosis Coexisting in a Case of Capgras Syndrome with Delusion of Subjective Doubles
by: ISHANI ROY CHATTERJEE
Published: (2024-02-01)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022-09-01)

Recent Onset Cardiometabolic Effects amongst Patients Started on Psychotropics: A Cohort Study
by: Prashant Maravi, et al.
Published: (2022-10-01)

Olanzapine as a Cause of Urinary Incontinence: A Case Report
by: Mobolaji Usman Dada, et al.
Published: (2012-09-01)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022-11-01)

Hippocampal Shape and Volume Changes with Antipsychotics in Early-Stage Psychotic Illness
by: Daniel eMamah, et al.
Published: (2012-11-01)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
by: Kaley Parchinski, et al.
Published: (2023-06-01)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
by: Anne Marciuch, et al.
Published: (2023-07-01)

Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine
by: Yong Zhao, et al.
Published: (2024-06-01)

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
by: Lingzhi Liang, et al.
Published: (2022-04-01)

Therapeutic Dosage of Antipsychotic Drug Aripiprazole Induces Persistent Mitochondrial Hyperpolarisation, Moderate Oxidative Stress in Liver Cells, and Haemolysis
by: Tinkara Pirc Marolt, et al.
Published: (2023-10-01)

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study
by: Lei Zhao, et al.
Published: (2023-08-01)

Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study
by: Subodh Kumar, et al.
Published: (2014-01-01)

Olanzapine-induced skin rash: A case report
by: Mansi Shah, et al.
Published: (2019-01-01)

Olanzapine in Treatment of Patients With Bipolar 1 Disorder And Panic Comorbidity: A Case Study
by: Lilijana Oruč, et al.
Published: (2003-11-01)

Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect
by: V. Ya Palatkin, et al.
Published: (2019-12-01)

Exploring delusional parasitosis – a case series of three patients
by: Abhishek Pathak, et al.
Published: (2024-04-01)

Effects of antipsychotics, haloperidol and olanzapine, on the expression of apoptosis-related genes in mouse mHippoE-2 cells and rat hippocampus
by: Osacka Jana, et al.
Published: (2023-01-01)

Rhabdomyolysis-Induced Acute Renal Injury in a Schizophrenic Patient
by: Tiglis Mirela, et al.
Published: (2020-11-01)

Novel Compounds in the Treatment of Schizophrenia—A Selective Review
by: Evangelia Maria Tsapakis, et al.
Published: (2023-08-01)

Effects of varenicline on the serum levels of olanzapine in male patients with Schizophrenia: a randomized controlled trial
by: Mengling Deng, et al.
Published: (2023-05-01)

Use of olanzapine compared with clozapine for treatment-resistant schizophrenia in a real-world setting: nationwide register-based study
by: Young Tak Jo, et al.
Published: (2021-09-01)

Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
by: Poh ME, et al.
Published: (2023-01-01)

Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
by: Taro Kishi, et al.
Published: (2019-09-01)

Evaluation of Different Doses of Fentanyl in Controlling Agitation in Acute Opioid Withdrawal Syndrome Induced by Naltrexone Misuse
by: Farzad Gheshlaghi, et al.
Published: (2012-03-01)

Chronic Intermittent Sucrose Consumption Facilitates the Ability to Discriminate Opioid Receptor Blockade with Naltrexone in Rats
by: David C. Jewett, et al.
Published: (2022-02-01)

Enhancing the aqueous solubility and dissolution of olanzapine using freeze-drying
by: Mudit Dixit, et al.
Published: (2011-12-01)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
by: Peng Z, et al.
Published: (2023-10-01)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
by: Jonathan Hindmarsh, et al.
Published: (2020-06-01)